Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.

Cryotherapy and steroid injections are similarly effective and safe for treating alopecia areata.

People with alopecia areata had lower vitamin D levels, but these levels didn't relate to many aspects of the condition.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

Mesenchymal Stem Cell Conditioned Media can significantly regrow hair in alopecia areata patients.

Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Women with type D personality and PCOS experience more stress and use less effective coping strategies.

Women with mixed alopecia have more severe mental health issues than those with metabolic alopecia.

No significant link between hair loss and iron or thyroid levels was found, but checking for deficiencies might still be useful.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.

Alopecia Areata is linked to a higher risk of several diseases, which vary with age and sex.

Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Azelaic acid 20% cream works well for treating scalp alopecia areata and can be an alternative to clobetasol ointment.

People with alopecia areata have much lower Vitamin-D levels than healthy individuals.

People with alopecia areata had lower vitamin D levels, but these levels did not relate to how severe their condition was.

People with alopecia have shorter hair follicles and more c-kit, a stem cell factor receptor, which could predict how the condition progresses.

PRP is an effective and safe treatment for alopecia areata.

Botulinum toxin type A did not help regrow hair in severe alopecia cases.

The document says how to diagnose and treat hair loss from alopecia areata, but there's no cure and treatments vary.

The patient with total hair loss did not regrow hair despite treatment, indicating a poor outlook for this type of hair loss.

A mix of methotrexate, corticosteroids, and topical minoxidil effectively treated severe total body hair loss, but caused stretch marks and needs long-term monitoring.

Men with early baldness often have low vitamin D levels.